Jani Leinonen, Renowned Finnish Artist, Is Releasing His First NFT on Swappable
Jani Leinonen, the renowned Finnish artist, will offer a 3 day NFT auction of his one-of-one animated artwork titled ‘Things You Own’, on Swappable, until Friday, August 27th at 10am PST. Swappable is a new interface for non-fungible tokens (NFTs) powered by TrustSwap.
Leinonen will be participating in an AMA Ask-Me-Anything event, offering the opportunity for the community to ask him questions.
Leinonen’s first NFT is supported by Stalla Madulain, the renowned Swiss art gallery dating back to 1488 and one of his most ardent supporters. As well as Switzerland-based international fine art logistics and infrastructure provider Haas & Company AG, a reputed partner of art collectors, galleries, museums, and art fairs worldwide which provides custody services for tokenized physical assets.
Swappable, powered by TrustSwap, will create a creative place for artists to sell their artworks and for users to find and collect artworks and digital collectibles. Jeff Kirdeikis, CEO of TrustSwap, mentions: “We are extremely excited to be working with such a renowned artist, we’ve created a platform that reduces the entrance barrier to the NFT space to support creators like Jani Leinonen.”
Leinonen is known for his provocative, yet playful works, criticizing capitalism and consumerism. In 2016, Leinonen was awarded the Finland Prize by the Ministry of Education and Culture, which is given in recognition of a significant career in arts. His work can be found in museums, and in private and public collections on every continent. He is currently exhibiting in Serlachius Museum with the street artist Banksy, and Salo Art Museum. The Five-star hotel Dolder Grand in Zurich has 12 of Leinonen’s works on permanent display. You can find out more about Leinonen on his website.
Jani Leinonen, on his NFT artwork ‘Things you own’: “Have we become more consumers than citizens? Our values, our political views, our emotions, traumas, and our dreams, are revealed by this sacred shopping cart. When we take a look at this portrait of us, how much do we recognize as our own? Will there truly be a new better world displacing the established and old, or will we forever be owned by the things we own?”
The team behind Swappable boasts that the Jani Leinonen collaboration is just the beginning, with many interesting collaborations to be revealed soon.
Swappable is the latest offering from TrustSwap
TrustSwap is a blockchain venture that offers smart contact services and innovative solutions for decentralized finance (DeFi) and commerce to help the crypto community transact with integrity, and accountability. TrustSwap solves problems in the DeFi space connected to tracking and buying crypto with ‘The Crypto App’, split payments, subscriptions, escrow, minting, token locks, and fundraising. TrustSwap is building foundational layers in the rapidly-emerging decentralized finance and commerce landscape with services like The Crypto App, SmartLocks, Mint, Launchpad, and Swappable’s NFT interface. Visit www.trustswap.org for information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005826/en/
Contact information
Howard Pearce
howard@trustswap.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom